Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002382 | 0.84 | GAA (0.50) | KDM4EGAAL3MBTL1F2F10 | |
| SCHEMBL7465385 | 0.80 | GAA (0.53) | KDM4EGAAKMT2ARECQLALDH1A1 | |
| SCHEMBL10443403 | 0.78 | L3MBTL1 (0.59) | KDM4EGAAL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL5754948 | 0.78 | ALDH1A1 (0.36) | KDM4EGAASIGMAR1KMT2ARECQL | |
| SCHEMBL11760578 | 0.77 | GAA (0.61) | KDM4EGAAKMT2ARECQLALDH1A1 | |
| SCHEMBL2003354 | 0.77 | GAA (0.45) | KDM4EGAAL3MBTL1F2F10 | |
| SCHEMBL1999856 | 0.76 | HDAC3 (0.52) | KDM4EGAABLMGRIN2DGRIN3B | |
| SCHEMBL7525897 | 0.76 | KDM1A (0.49) | KDM4EGAAL3MBTL1F2F10 | |
| SCHEMBL10816174 | 0.74 | KDM4E (0.42) | KDM4EGAAF2F10F12 | |
| SCHEMBL467514 | 0.74 | NPC1 (0.57) | KDM4EGAAGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462592-B2 | Compositions and methods for polynucleotide delivery | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-09 | — | — | US | claimed |
| US-20080089938-A9 | Compositions and methods for polynucleotide delivery | ZUCKERMANN RONALD N | 2008-04-17 | — | — | US | claimed |
| US-20040024000-A1 | Dihydropyrimidine derivatives as cysteine protease inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2004-02-05 | — | — | US | claimed |
| EP-0941122-B1 | COMPOSITIONS FOR POLYNUCLEOTIDE DELIVERY | CHIRON CORP (US) | 2003-10-29 | — | — | EP | claimed |
| US-20030185890-A1 | Compositions and methods for polynucleotide delivery | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2003-10-02 | — | — | US | claimed |
| EP-1194428-B1 | HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS | DIMENSIONAL PHARM INC (US) | 2003-09-17 | — | — | EP | claimed |
| EP-1326848-A1 | DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2003-07-16 | — | — | EP | claimed |
| US-6468986-B1 | COMPOSITION COMPRISING POLYNUCLEOTIDE AND POLYCATIONIC AGENT WHICH EXHIBITS NET POSITIVE ELECTRICAL CHARGE AT PHYSIOLOGICAL PH, AND IS CAPABLE OF MEDIATING ENTRY OF POLYNUCLEOTIDES INTO CELL | CHIRON CORPORATION | 2002-10-22 | — | — | US | claimed |
| US-6420397-B1 | Heteroaryl protease inhibitors and diagnostic imaging agents | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | claimed |
| WO-2002032879-A1 | DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2002-04-25 | — | — | WO | claimed |
| EP-1194428-A1 | HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-04-10 | — | — | EP | claimed |
| US-6251433-B1 | Polycationic polymers | CHIRON CORPORATION | 2001-06-26 | — | — | US | claimed |
| WO-2001004117-A1 | HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-01-18 | — | — | WO | claimed |
| EP-0941122-A2 | COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY | CHIRON CORPORATION (US) | 1999-09-15 | — | — | EP | claimed |
| EP-0615978-B1 | Peptide derivatives of the boronic acid having protease inhibiting activity, process for their production and pharmaceutical compositions comprising them | ADIR (FR) | 1999-05-12 | — | — | EP | claimed |
| WO-1998006437-A2 | COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY | CHIRON CORPORATION (US) | 1998-02-19 | — | — | WO | claimed |
| EP-0615978-A1 | Peptide derivatives of the boronic acid having protease inhibiting activity, process for their production and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 1994-09-21 | — | — | EP | claimed |
| US-4310459-A | Process for producing carbamoyl substituted penams and carbamoyl substituted cephams from penicillin sulfoxide esters | BRISTOL-MYERS COMPANY (US) | 1982-01-12 | — | — | US | claimed |
| US-9353170-B2 | Long-acting transient polymer conjugates of exendin | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-05-31 | — | — | US | disclosed |
| US-4285932-A | Enzyme derivatives for use in the treatment of venous thrombosis | BEECHAM GROUP LIMITED (GB) | 1981-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089938-A9 | Compositions and methods for polynucleotide delivery | POLN, RNASE1, NCL | KDM4E 4360/4885GAA 348/4885L3MBTL1 1695/4885 |
| US-20040024000-A1 | Dihydropyrimidine derivatives as cysteine protease inhibitors | DPEP1, DNPEP, PEPD | KDM4E 3705/4885GAA 523/4885L3MBTL1 1429/4885 |
| US-20030185890-A1 | Compositions and methods for polynucleotide delivery | POLN, RNASE1, NCL | KDM4E 4360/4885GAA 348/4885L3MBTL1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.